In pursuit of attempts at a systematic study of autosomal trisomy in the mouse, an experimental model is presented which permits the induction of specific trisomic conditions. It is based on (1) the occurrence of considerable rates of meiotic anaphase I malsegregation of double metacentric heterozygotes with monobrachial homology, (2) the expectation that trisomics may be found among the unbalanced conditions in the progeny of crosses of the double heterozygotes with “all acrocentric” mice, and (3) the observation that trisomy, in contrast to monosomy or combined monosomy plus trisomy, is the only unbalanced condition surviving beyond day 10. In this design, the specific nature of the trisomy is predetermined by the choice of the double metacentric heterozygote combination and recognized by such criteria as chromosome arm number and the presence of both metacentrics. All trisomic conditions of the mouse so far studied inevitably lead to early or late fetal death. Although the possibility of a systematic survey of all 19 possible autosomal trisomies in the mouse can be anticipated, this report is limited to a study of trisomies (Ts) 1, 8, 11, 12, and 17. Ts 8, 11, and 17 cause severe developmental inhibition at an early stage of development. Death occurs about day 11 or 12. Ts 1 displays a syndrome of moderate to marked developmental retardation and slight to more distinctly disproportionate hypoplasia. These embryos may survive until day 15. In contrast, a lesser extent of hypoplasia and retardation is observed in Ts 12, which, however, almost regularly shows exencephaly and microphtalmia. Obviously, variation of the severity of phenotypic manifestation of the trisomic conditions is due to genie heterogeneity of the animals used in the present study. Current attempts are directed to introduce a sufficient number of metacentrics in a defined background, thus providing the means for future systematic studies of the phenotypic expression of gross genomic imbalance.
Request reprints from: Dr. Alfred Gropp, Abteilung für Pathologie der Medizinischen Hochschule Lübeck, Ratzeburger Allee 160, 24 Lübeck 1 (Federal Republic of Germany).
Manuscript received: 11 September 1974
Published online: April 30, 2008
Number of Print Pages : 21
Cytogenetic and Genome Research
Vol. 14, No. 1, Year 1975 (Cover Date: 1975)
Journal Editor: Schmid M. (Würzburg)
ISSN: 1424–8581 (Print), eISSN: 1424–859X (Online)
For additional information: http://www.karger.com/CGR
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.